Sanofi and CD&R sign Opella share purchase agreementParis, February 19, 2025. Following completion of the required social and corporate ...

The decision to divest Opella is part of Sanofi’s ongoing strategy to become a pureplay biopharma company. Opella employs more than 11,000 people worldwide and is known for making Doliprane ...

Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

The sale of Sanofi's controlling stake in health business Opella is expected to close in ... but added that the company will still take a balanced approach to deals. Sanofi, one of the world's ...

2% stake in Opella, with Sanofi remaining a significant shareholder ... We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people ...

2% stake in Opella, with Sanofi remaining ... approvals from the competent authorities. About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles ...